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I is actively transported into thyrocytes via the Na/I sym-
porter (NIS), a key glycoprotein located on the basolateral
plasmamembrane. The cDNA encoding rat NISwas identified
in our laboratory, where an extensive structure/function
characterization of NIS is being conducted. Several NIS mu-
tants have been identified as causes of congenital I transport
defect (ITD), including V59E NIS. ITD is characterized by low
thyroid Iuptake, low saliva/plasma I ratio, hypothyroidism,
and goiter and may cause mental retardation if untreated.
Studies of other ITD-causingNISmutants have revealed valu-
able information regarding NIS structure/function. V59E NIS
was reported to exhibit as much as 30% of the activity of
wild-typeNIS.However, this observationwasat variancewith
the patients’ phenotype of total lack of activity. We have thor-
oughly characterized V59E NIS and studied several amino
acid substitutions at position 59. We demonstrated that, in
contrast to the previous report, V59ENIS is inactive, although
it is properly targeted to the plasma membrane. Glu and all
other charged amino acids or Pro at position 59 also yielded
nonfunctional NIS proteins. However, I uptake was rescued
to different degrees by the other substitutions. Although the
Km values for Na
 and I were not altered in these active
mutants, we found that the structural requirement for NIS
function at position 59 is a neutral, helix-promoting amino
acid. This result suggests that the region that contains V59
may be involved in intramembrane helix-helix interactions
during the transport cycle without being in direct contact
with the substrates. (Endocrinology 149: 3077–3084, 2008)
IODIDE (I) IS AN ESSENTIAL component of the thyroidhormones T3 and T4, which are required for development
and maturation of the central nervous system, skeletal mus-
cle, and lungs of the fetus and the newborn and for inter-
mediary metabolism in virtually all tissues (1). The Na/I
symporter (NIS), a highly specialized glycoprotein located
on the basolateral membrane of the thyroid epithelial cells,
couples the inward translocation of two Na down their
electrochemical gradient to the simultaneous inward trans-
location of one I against its electrochemical gradient (2). The
driving force for NIS activity is the Na gradient generated
by the Na/K ATPase.
For decades, I uptake in the thyroid has been used for the
diagnosis and treatment of several thyroid conditions. How-
ever, the molecular analysis of NIS only started in 1996, when
our group identified the cDNA that encodes rat NIS (rNIS)
(3). In addition to the thyroid, NIS is also expressed in other
tissues such as the salivary and lactating mammary glands
and gastric mucosa (4, 5). NIS expression in the lactating
mammary gland is responsible for transporting I into the
milk, thus enabling the nursing infant to produce his/her
own thyroid hormones (6).
Congenital I transport defect (ITD) is a rare autosomal
recessive disease defined by a lack of I transport (and there-
fore an absence of thyroid hormones) and, when untreated,
characterized by hypothyroidism, goiter, mental retardation,
and a diminished saliva/plasma I ratio (4, 7). With the
isolation of the NIS cDNA, the identification and molecular
characterization of mutant NIS molecules that cause ITD
became feasible. To date, 12 ITD-causing NIS mutations have
been reported (V59E, G93R, R124H, M143-Q323, Q267E,
C272X, T354P, G395R, A439-P443, frame-shift 515X, Y531X,
and G543E) (8–18) (Fig. 1). Several of these have been thor-
oughly characterized in our laboratory, yielding important
information on NIS structure/function (19–22). Thus, the
analysis of T354P NIS (22) led not only to the conclusion that
an amino acid with a hydroxyl group at its -carbon at
position 354 is necessary for NIS function but also to the
finding that other amino acids within transmembrane seg-
ment (TMS) IX (the segment with the highest incidence of
amino acids with hydroxyl groups at -carbons) have the
same requirement for NIS function. This observation, in turn,
provided the basis for the identification of residues that may
be involved in the Na translocation pathway (23). The char-
acterization of the G395R NIS mutant showed that NIS ac-
tivity requires a small, uncharged amino acid at position 395
(21). We reported that Q267E NIS is properly targeted to the
plasma membrane but only transports modest amounts of I
because of a decrease in the NIS kinetic turnover number
(19). In contrast, we determined that G543E NIS does not
fully mature and is retained intracellularly as a result of the
charge and size of Glu (20).
The V59E NIS mutation was discovered as a compound
heterozygous mutation in all three children of a Japanese
couple in 2000 (10). The parents themselves had no thyroid
dysfunction. This family was first described in 1977 (24),
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before the molecular identification of NIS. After the NIS
cDNA was isolated (3, 25), Fujiwara et al. (10) determined in
their 2000 study that the patients inherited the T354P and
V59E NIS mutations from their mother and father, respec-
tively. That all three siblings had this genotype is remarkable,
given the 1/64 likelihood in a normal Mendelian inheritance.
Amino acid 59 is located on the cytosolic side of putative TMS
II, a region of NIS that is well conserved in all species in
which NIS has been sequenced and throughout the SLC5A
transporter family, suggesting that this residue plays a role
in NIS structure and/or I transport (26). Fujiwara et al. (10)
transfected cDNA constructs encoding V59E and reported
that I transport in cells expressing V59E NIS was almost
30% of that exhibited by wild-type (WT) NIS. The authors
concluded from these data that V59E NIS was not completely
inactive, even though this notion is in conflict with the clin-
ical data indicating no activity (saliva/plasma I ratios of
1). In addition, the study lacked the negative controls (i.e.
transport in the presence of the inhibitor ClO4
 or in the
absence of Na) needed to support their conclusions. Hence,
to determine to what extent and by what mechanism the
V59E substitution disrupts NIS function, we have carried out
a thorough molecular characterization of V59E NIS using a
variety of methods, including flow cytometry, I transport
assays, immunoblot, immunofluorescence, and cell surface
biotinylation.
Materials and Methods
Site-directed mutagenesis
Site-directed mutagenesis was performed using the following oligos:
V59A, GCA GCC GTT CCT SCG GGG CTG TCG; V59D, GCA GCC GTT
CCT RAC GGG CTG TCG; V59E, GCA GCC GTT CCT SAG GGG CTG
TCG; V59I, GCA GCC GTT CCT ATT GGG CTG TCG CTG; V59K, GCA
GCC GTT CCT ARG GGG CTG TCG; V59L, GCA GCC GTT CCT CTG
GGG CTG TCG CTG; V59M, GCA GCC GTT ATG GGG CTG TCG CTG;
V59N, GCA GCC GTT CCT RAC GGG CTG TCG; V59P, GCA GCC GTT
CCT SCG GGG CTG TCG; V59Q, GCA GCC GTT CCT SAG GGG CTG
TCG; V59R, GCA GCC GTT CCT ARG GGG CTG TCG; V59T, GCA GCC
GTT CCT ACG GGG CTG TCG CTG; and the T354P oligo was the same
as in Levy et al. (22). Site-directed mutagenesis was carried out as
previously described (27). The initial PCR extensions were performed
using reverse primers complementary to the 3 end. These fragments
were gel purified and used for a second round of PCR extension with
primers complementary to the 5 end. Fragments with the mutant se-
quences were obtained by digestion of the final PCR products with the
appropriate unique restriction enzyme to obtain the smallest mutant
fragments. These fragments were then ligated into WT NIS cDNA (PS-
VSport-rNIS), and the mutant inserts were sequenced past their respec-
tive cloning sites.
Cell culture and transient transfection of COS-7 cells
COS-7 cells were grown at 37 C with 5% CO2 and maintained in
DMEM before transient transfection with 4 g/plate rat NIS cDNA
constructs using Lipofectamine Plus (Invitrogen, Carlsbad, CA) follow-
ing the manufacturer’s instructions. Transfected cells were split 24 h
after transfection and analyzed by immunoblot, surface biotinylation,
and immunofluorescence, assayed for I uptake, and measured by
FACS to measure transfection efficiency 48 h after transfection.
Immunoblot analysis
Transiently transfected cells were lysed by incubating them with
complete lysis buffer [1% SDS, 50 mm Tris (pH 7.4), 150 mmNaCl, 5 mm
EDTA, and 1% Triton X-100] and then adding lysis buffer (complete lysis
buffer without SDS) at a dilution of 1:10. After cell lysis, the protein
concentration was quantified using the BCA protein measurement kit
(Pierce, Rockford, IL). Samples were diluted with sample buffer and
incubated at 37 C for 30 min followed by 9% SDS-PAGE, electroblotted
to a nitrocellulose membrane, and immunoblotted with 2 nm of an
affinity-purified anti-rNIS polyclonal antibody (directed against the last
16 amino acids of the rNIS C terminus) for 1 h and then incubated for
45 min with the antirabbit HRP secondary antibody (Jackson Laboratory,
Bar Harbor, ME).
Cell surface biotinylation
Biotinylation of cell surface proteins was performed as previously
described (19). Twenty-four hours after transfection, COS-7 cells were
split into 12-well plates and maintained in DMEM for 24 h more. Tran-
siently transfected cells were incubated with 1 mg/ml of the membrane-
impermeable biotin reagent sulfo-succinimidyl 2-(biotinamido)-ethyl-
1,3-dithiopropionate-biotin (sulfo-NHS-SS-biotin) (Pierce), which
covalently interacts with extracellular primary amines. The reaction was
subsequently quenched with 100 mm glycine in PBS supplemented with
1 mm MgCl2 and 0.1 mm CaCl2. Cells were lysed and biotinylated
proteins precipitated overnight with streptavidin-coated beads, heated
with sample buffer containing 100 mm final dithiothreitol at 75 C for 5
min, subjected to SDS-PAGE, and immunoblotted with anti-rNIS. As a
control, supernatants obtained after the overnight incubation were an-
alyzed by immunoblot.
Steady-state I transport analysis
Transfected cells were assayed under steady-state conditions in trip-
licate. Forty-eight hours after transfection, cells were washed twice in
Hanks’ buffered salt solution (HBSS) [140 mmNaCl, 5.4 mmKCl, 1.3 mm
CaCl2, 0.4 mm MgSO4, 0.5 mm MgCl2, 0.4 mm NaHPO4, 0.44 mm
KH2PO4, and 5.55 mm glucose in 10 mm HEPES (pH 7.5)]. Cells were
then incubated with 20 m K125I (specific activity 100 mCi/mmol) and
140 mm Na (unless otherwise indicated) for 45 min to 1 h at 37 C in a
humidified atmosphere with 5% CO2 and then washed twice more with
HBSS (4 C). Accumulated I was released by incubating cells with 100%
ethanol for at least 20 min at 4 C and quantitated in a -counter (Perkin-
Elmer, Norwalk, CT). I uptake was standardized by determining the
amount of DNA per well by incubating cells with 5% trichloroacetic acid
for 30 min at 4 C followed by an overnight incubation with diphe-
nylamine solution.
I- and Na-dependent kinetic analysis
For I-dependent kinetic analysis, cells were incubated with I con-
centrations ranging from 0.6–80 mNa125I and 140 mmNaCl for 2 min.
FIG. 1. Schematic representation of the NIS secondary structure
model. The current secondary structure model of NIS depicts 13 TMS
(labeled with Roman numerals) with an extracellular N and a cyto-
solic C terminus. The 12 ITD-causing NISmutations are indicated by
the single-letter amino acid code, showing theWT residue followed by
the position number and the substituted residue. FS, Frame shift; X,
premature stop codon; , deletion.
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Initial rates of I transport measured during kinetic analysis were an-
alyzed by nonlinear regression using the following equation: v([I]) 
(Vmax [I
])/(Km  [I
])  A  [I]  B. The terms A and B refer to
background adjusted by least squares of the data obtained with non-
transfected cells. For the Na-dependent kinetic analysis, cells were
incubated with 20mNa125I and a range of Na concentrations between
0 and 140 mm for 2 min (isotonicity was maintained using choline-Cl).
The equation used to analyze the initial rates is v([Na])  (Vmax
[Na]2)/(Km
2  [Na]2)  A  [Na]  B. Data were analyzed by
gnuplot (www.gnuplot.info).
Results
V59E NIS is expressed but inactive
To assess the transport properties of V59E NIS, we mea-
sured Na-dependent, perchlorate (ClO4
)-inhibitable (i.e.
NIS-mediated) I transport at 20 m I and 140 mmNa for
1 h in COS-7 cells expressing either V59E NIS or WT NIS. WT
NIS-expressing cells accumulated 80–100 pmol I/g DNA;
I uptake was inhibited by 40 m ClO4
. Cells expressing
V59E NIS showed no I transport, just like nontransfected
COS-7 cells (Fig. 2A). FACS analysis revealed that the trans-
fection efficiency of WT and V59E NIS was similar (data not
shown). Cell lysates from transfected COS-7 cells were sub-
jected to SDS-PAGE and immunoblotted with a high-affinity
anti-rNIS antibody. NIS expression levels were similar in
cells transfected with WT or V59E NIS (Fig. 2B), each ex-
pressing the characteristic fully glycosylated mature (110
kDa) and the partially glycosylated immature polypeptide
(55 kDa). In contrast, no polypeptides were detected in cell
lysates from nontransfected COS-7 cells, which do not ex-
press endogenous NIS. The endogenously expressed -sub-
unit of the Na/K ATPase was used as a loading control
(Fig. 2B).
V59E NIS is properly targeted to the plasma membrane
Whereas the lack of I transport mediated by the ex-
pressed V59E NIS protein (Fig. 2) suggested that it is inher-
ently incapable of transporting I, it was also possible that
V59E NIS was not targeted to the plasma membrane. Indeed,
previous analysis of other ITD-causing NIS mutants revealed
a lack of I transport due to improper targeting of the mutant
NIS proteins to the cell surface (20). Therefore, we assessed
the presence of V59E NIS in the plasma membrane by cell
surface biotinylation. Transfected COS-7 cells were treated
with sulfo-NHS-SS-biotin, a membrane-impermeable biotin
reagent that covalently interacts with extracellular primary
amines. Immunoblot analysis of the biotinylated cell surface
proteins in cells transfected with WT NIS showed a maturely
glycosylated NIS polypeptide, represented by a broad band
at about 110 kDa, indicating that, as expected, WT NIS is
properly processed and targeted to the cell surface, where it
mediates I uptake. V59E NIS was also properly targeted to
the plasma membrane. The endogenously expressed -sub-
unit of the Na/K ATPase was used as a loading control.
In contrast, the soluble protein tubulin was not biotinylated
(data not shown). Therefore, the observed lack of I transport
is not due to improper protein maturation or faulty traffick-
ing to the plasma membrane (Fig. 2C).
The presence of charged amino acids or Pro at position 59
of NIS renders the protein inactive
One possible explanation for the inactivity of the V59E NIS
protein is the presence of the negatively charged side chain
of Glu instead of the neutral side chain of Val at position 59.
Thus, we substituted Val with other charged amino acids
(Asp, Arg, and Lys). In addition, we also evaluated the effect
of Pro, an -helix breaker, at position 59. None of the NIS
mutants with a charged residue or Pro at position 59 dis-
played I transport (Fig. 3A), even though all (except the Pro
mutant) were expressed at levels similar to those of WT NIS
(Fig. 3B) and all were properly targeted to the plasma mem-
brane, as determined by cell surface biotinylation (Fig. 3C).
The endogenously expressed-subunit of the Na/KATPase
was used as a loading control. These results show that the
presence of a charged amino acid or a Pro at position 59 renders
NIS inactive.
Neutral amino acids at position 59 rescue NIS activity
The neutral amino acids Ala, Asn, Gln, Ile, Leu, Met, and
Thr were individually substituted instead of Val at position
59. Each of the resulting NIS mutant proteins displayed I
transport at different levels, all significant but lower than
those of WT NIS (Fig. 4A). Interestingly, mutants with amino
acids at position 59 that had, like Val, branched side chains
at the -carbon (i.e. Ile and Thr) exhibited I transport at
levels comparable to those of WT NIS, independently of the
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FIG. 2. Characterization of activity and expression of V59E NIS in
COS-7 cells. A, Steady-state I uptake analysis in nontransfected
(NT) COS-7 cells or cells transfected with eitherWT or V59ENISwas
determined. Cells were incubated for 1 h in HBSS containing 140 mM
Na and 20 M 125I (black bars) or HBSS containing 140 mM Na
and 20 M 125I and 40 M ClO4
 (white bars); accumulated I was
measured in a -counter and standardized bymicrograms of DNA.NT
cells represent background levels of I transport. Values are ex-
pressed as a percentage of the activity of WT NIS (typically 80–100
pmol I/g DNA). Values represent the average of at least three
different experiments; in each experiment, transport measurements
were performed in triplicate. B, Immunoblot analysis. Cell lysates (2
g) from nontransfected (NT) cells or cells transfected with eitherWT
NIS or V59E NIS (E) were electrophoresed, electrotransferred, and
immunoblotted with 2 nM anti-rNIS. C, Cell surface biotinylation.
Transfected cells were incubated with the membrane-impermeable
sulfo-NHS-SS-biotin reagent (1 mg/ml) and precipitated overnight
with streptavidin beads. Streptavidin beads and bound biotinylated
proteins were heated in sample buffer at 75 C, and the cell surface
biotinylated proteins were immunoblotted with 2 nM anti-rNIS. The
-subunit of the Na/KATPase was used as a loading control (B and
C, bottom panels).
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residue side-chain volume. Each of these NIS mutants was
normally expressed after transfection into COS-7 cells (Fig.
4B), and each was also correctly targeted to the plasma mem-
brane, as shown by cell surface biotinylation (Fig. 4C). The
endogenously expressed -subunit of the Na/K ATPase
was used as a loading control.
The decreased I transport in NIS mutants with neutral
amino acid substitutions at position 59 is due to a change
in Vmax
We performed kinetic analyses of those NIS mutants that
displayed I transport (i.e. those containing Ala, Asn, Ile,
Leu, Met, Gln, or Thr at position 59) to determine whether or
not the change in I transport with respect to WT NIS was
due to a decrease in the apparent affinity of NIS for Na or
I (as reflected by a change in the respective Km values) or
to a lower NIS kinetic turnover number (as reflected by a
change in the Vmax). Cells were incubated with different
concentrations of I (ranging from 0.6–80 m) and 140 mm
Na for 2 min to measure the initial rates of I transport (Fig.
5A). Na-dependent kinetic experiments with the same NIS
mutants using Na concentrations from 0–140 mm and 20
m I were also performed to measure initial I transport
rates as a function of the Na concentration (Fig. 5B). In both
cases, each mutant protein exhibited Km values similar to
those of WT NIS but a lower Vmax (Fig. 5C). Therefore, de-
creased transport in these mutants results from a lower NIS
kinetic turnover.
The V59E/T354P NIS compound mutation is inactive
After demonstrating that V59E NIS is inactive, we decided to
experimentally test the compound V59E/T354P NIS mutation
because it is expressed in the three Japanese patients. To prop-
erly assess I uptake mediated by V59E/T354P NIS in relation
to that mediated by WT NIS, we cotransfected 2 g V59E and
2 g T354P NIS cDNA into COS-7 cells and compared it with
transport in cells transfected with 2 or 4g WT, V59E, or T354P
NIS cDNA. In contrast to the results from Fujiwara et al. (10),
who reported that V59E/T354P NIS exhibited approximately
20% of WT NIS I transport levels, we observed no I accu-
mulation mediated by the compound mutant. Transfection ef-
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NIS and analyzed as follows. A, Steady-state I transport in cells
incubated with 20 M I and 140 mM Na (black bars) and in cells
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FIG. 4. NIS is active with neutral amino acids other than Pro at
position 59. COS-7 cells were transfected with V59A, I, L, M, N, Q, T,
or WT NIS cDNAs and analyzed as follows. A, Steady-state I trans-
port in cells incubated with 20 M I and 140 mM Na (black bars)
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the amino acid substitutions that are branched at the-carbon (as Val
is), which yield the proteins that mediate the highest levels of I
accumulation compared with WT NIS. B, Immunoblot analysis. C,
Cell surface biotinylation. The -subunit of the Na/K ATPase was
used as a loading control (B and C, bottom panels).
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ficiency of the mutant NIS constructs into COS-7 cells was
measured by FACS analysis (not shown). An immunoblot of the
cell lysates showed that the cotransfected NIS cDNA constructs
were expressed at levels similar to WT NIS (Fig. 6A). Compar-
ison of the signals visualized by immunoblotting the membrane
proteins after cell surface biotinylation indicated that the ma-
ture polypeptides expressed after cotransfection reached the
plasma membrane at amounts comparable to those of WT NIS
(Fig. 6B). Still, we observed no I accumulation in COS-7 cells
expressing V59E/T354P NIS, a finding consistent with the pa-
tients’ phenotypes (Fig. 6C).
Discussion
The V59E NIS mutation was identified in three siblings in
Japan (10, 24). The patients were heterozygous for both the
T354P NIS mutation (inherited from their mother) and the
V59E NIS mutation (inherited from their father). The three
siblings had ITD, whereas their parents were healthy, com-
patible with the autosomal recessive character of ITD. Fuji-
wara et al. (10) cotransfected HEK293 cells with cDNA con-
structs encoding V59E and T354P NIS and reported 20% of
WT NIS I transport in these cells, whereas HEK293 cells
expressing V59E NIS transported almost 30% of WT NIS I
transport. However, in the absence of I transport experi-
ments in nontransfected cells and without a study of the
effect of ClO4
 in NIS-transfected cells, it is not possible to
discriminate between NIS-mediated I uptake and nonspe-
cific I binding and/or transport. In addition, the levels of
expression of the different NIS proteins were not determined.
Without this information, it is not feasible to accurately as-
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FIG. 5. A, I-dependent kinetic assays. cDNA
constructs encoding WT NIS or NIS with amino
acids at position 59 thatwere conducive to activity
(V59A, I, L, M, N, Q, and T) were assayed for
initial I transport rates (2 min) as a function of
different I concentrations, ranging from
0.6125–80M, at a constant Na concentration of
140mMNa. Vmax and Km values were calculated
with the equation v([I])  (Vmax [I
])/(Km 
[I])  A  [I]  B and the gnuplot program. B,
Na-dependent kinetic assays. Cells were as-
sayed to determine the initial rates of I transport
as a function of the external [Na]. Cells were
assayed for initial I transport rates (2 min) as a
function of different Na concentrations, ranging
from 0–140 mM, at a constant I concentration of
20 M. Results were analyzed using the gnuplot
program and applied to the equation v([Na]) 
(Vmax [Na
]2)/(Km
2  [Na]2)  A  [Na]  B
to determine Vmax and Km. C, Average Km (I
 and
Na) andVmax (I
 andNa) values as determined
by kinetic analysis. The table lists the averageKm
and Vmax values from six I
-dependent kinetic
assays (left) and six Na-dependent kinetic as-
says (middle); in each experiment, activity was
analyzed in triplicate. On the right, the position
of the amino acid side chain of each amino acid is
listed. The variation in Vmax and the lack of sig-
nificant variation of Km values indicate that the
decreased levels of I accumulation are not due to
a change in the apparent affinity of the mutant
NIS proteins for Na or I. Interestingly, the
amino acids that are branched at the -carbon
(such as Ile or Thr), i.e. equal to Val, accumulated
the highest levels of I. Graphs in A and B cor-
respond to a representative experiment.
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sess NIS-mediated (i.e. Na-dependent, ClO4
-inhibitable)
I transport.
These authors’ findings regarding the partial activity of
V59E NIS contrast with our own observation that this mutant
is inactive (Fig. 2), which is fully consistent with the lack of
active I transport reported in the thyroid and salivary
glands of the patients (24). The patients in whom the V59E
NIS substitution was identified also carry the previously
characterized T354P NIS substitution (22). Because ITD is an
autosomal recessive disease and the three patients have ITD,
both mutant NIS alleles inherited by the children must be
inactive. Indeed, we have characterized the V59E NIS protein
and determined that it is intrinsically inactive. Based on
previous studies of some ITD-causing mutations, possible
explanations for the inactivity caused by the replacement of
Val with Glu include an inability to properly process and/or
target the mutant protein to the plasma membrane (20) or a
decreased ability to catalyze I transport owing to the dif-
ference in size and/or charge of the amino acid replacement
(19, 21, 22); we investigated each of these possibilities.
Here we present a thorough analysis of the V59E NIS
mutation and report that it renders NIS inactive because of
the presence of the charged amino acid Glu, despite proper
protein expression and plasma membrane targeting (Fig. 2).
Furthermore, neutral amino acids branched at the -carbon
(Val, Ile, and Thr) and Ala were most conducive to NIS
transport, compared with the other neutral amino acids that
were substituted (Leu, Met, Gln, and Asn) (Fig. 4), whereas
the presence of a charged amino acid prevented NIS activity,
as did Pro (this result is most likely due to a bend in -helix
formation) (Fig. 3). Lastly, we determined that the reduction
in I transport observed in the mutant NIS molecules that are
capable of transporting I (V59A, I, L, M, N, Q, and T) was
due to a decrease in NIS kinetic turnover, as opposed to a
change in the apparent affinity of the transporter for Na or
I (Fig. 5).
According to our proposed secondary structure model
(Fig. 1) (27), V59 is located in TMS II, close to the interface
with the cytosol. The best explanation for our experimental
data is that V59 is involved in intramembrane helix-helix
contact. Given that all NIS mutants with substitutions at
position 59 reached the cell surface, we conclude that charged
residues at this position do not seem to affect correct folding
and targeting; however, charged residues rendered NIS in-
active, suggesting that accommodation of a charge of either
polarity requires a large realignment of the two contacting
helices so as to allow the charge to be compensated by a
mobile charge at the membrane-cytosol interface. Replace-
ments of V59 with neutral amino acids resulted in different
levels of NIS activity, except for Pro, which rendered the
protein inactive, most likely due to a disruption in -helix
formation (28). On the other hand, the activity elicited by the
other neutral residue substitutions cannot be explained on
the basis of their helical propensity properties, which relate
to the relative stability of helices having different amino acids
at a particular position, given that Met has long been rec-
ognized as a strong helix former (30). In general terms, small
(Ala) and -branched (Val, Ile, and Thr) residues led to
higher NIS activity, probably because they allow the WT
orientation of the helices to be preserved, whereas larger
residues (Leu, Met, Gln, and Asn), although still yielding
active proteins, led to lower NIS activity, probably because
of a small rearrangement of the two helices involved. Elu-
cidation of the three-dimensional structure of NIS would
clarify the nature of the proposed helix-helix interactions.
The question remains as to how to explain the marked
differences among the three siblings in phenotype and their
improvement in thyroid function and clinical condition after
treatment with KI. Fujiwara et al. (10) implicitly argue that
when NIS function is diminished, excess I supply could
compensate for the decreased transport capacity of NIS, and
that differences in dietary I content could account for the
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FIG. 6. Expression, plasma membrane targeting, and activity of
V59E/T354P NIS. A, Immunoblot analysis. Cell lysates (2 g) from
COS-7 cells cotransfected with 2 g each of V59E and T354P or
transfected with 4 g WT NIS were subjected to SDS-PAGE and
immunoblotted with 2 nM anti-rNIS. B, Cell surface biotinylation. C,
I uptake. V59E and T354PNIS cDNA (2g each) were cotransfected
into COS-7 cells, and I accumulation was compared with that of
V59E, T354P, or WT NIS cDNA (4 g). Shown is I transport in cells
incubated with 20 M I and 140 mM Na (black bars) or with 20 M
I, 140 mM Na, and 40 M ClO4
 (white bars). Values are a per-
centage of WT NIS activity. Values represent the average of at least
three different experiments; in each experiment, activity was ana-
lyzed in triplicate.
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variability in phenotypes as observed in the three siblings
(10). Their statement that NIS activity was not completely
abolished is, as stated above, not compatible with the saliva/
plasma I ratios of approximately 1, as found in all three
patients. The clinical diagnosis of absence of NIS-mediated
I uptake, experimentally proven by the complete lack of I
transport mediated by the same NIS mutants when trans-
fected into COS-7 cells, leaves no other conclusion than that
other mechanisms of I entry into the thyroid must be
present. The KI treatment that the siblings received (14 mg
KI/d) is approximately 100 times the World Health Orga-
nization-recommended daily dietary I supply (150 g/d)
(30). In addition, Toyoshima et al. (24) stated that the Japanese
diet has a median daily I content of 1.5 mg/d (24). Assum-
ing a distribution volume of I of about 2.5 liters in children,
the plasma I concentration in the siblings would have been
approximately 164 m, compared with 0.88 m in adults in
Western countries. It cannot be ruled out that at those high
plasma I concentrations, other channels or transporters
such as Cl channels or cystic fibrosis transmembrane con-
ductance regulator (CFTR) may transport I into the thyroid
(31, 32). Even then, it is remarkable that this bypass appar-
ently leads to sufficient thyroid hormone production and
physical development in the absence of NIS.
Toyoshima et al. (24) reported that the mother of the three
siblings consumed large quantities of laminaria, a dried kelp
that contains 302 mg I/100 g. Interestingly, there was a
strong correlation between the severity of the ITD symptoms
in the three siblings and their feeding habits during infancy.
The two oldest siblings exhibited symptoms of ITD that were
significantly less severe than those of the youngest sibling.
The oldest sibling was fed only the mother’s milk, which
contained I (because NIS is expressed in the lactating mam-
mary gland) (6), and had the least severe ITD symptoms. The
middle sibling was fed a combination of the mother’s milk
and cow’s milk and exhibited symptoms less severe than
those of the youngest sibling, who was fed only cow’s milk.
Interestingly, it seems that the large quantities of laminaria
consumed by the mother provided the two oldest children
enough I to produce T3 and T4, as did the 14-mg doses of
KI that were taken later in life.
Our studies show that V59E NIS is inactive (as is T354P NIS).
TheITDsymptomsobservedinthesiblingswereamelioratedafter
treatment with high doses of I, first with the two older siblings
whose cases of ITD were mild because of high I concentrations
in their diet as infants and later in life to the 14 mg KI treatment,
suggesting that when plasma I levels are extremely high, I
enters the thyroid by way of other channels or transporters.
In summary, we have thoroughly analyzed V59E NIS and
V59E/T354P NIS and determined that the presence of a
charged residue at position 59 in NIS completely impairs I
transport. We determined that the structural requirement at
that position is a branched residue to allow proper helix-helix
contact and the correct NIS kinetic turnover number. The pa-
tients’ clinical data published by Toyoshima et al. (24) indicate
that the severity of the symptoms in each child was related to
whether or not and for how long they were breastfed. This
observation underscores the importance of providing adequate
amounts of I to infants, whether in maternal milk or formula,
to ensure normal physical and mental development.
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